1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsCoordinating and Data Management Center for Translational and Basic Science Research in Early Lesions is sponsored by National Cancer Institute (NCI). Provides support for coordinating and managing data in research focused on early lesions in cancer detection.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Translational and Basic Science Research in Early Lesions (TBEL) Program | Division of Cancer Prevention Translational and Basic Science Research in Early Lesions (TBEL) Program The Translational and Basic Science research in Early Lesions (TBEL) program is a collaborative research network that aims (1) to further understand the biological and pathophysiological mechanisms driving or restraining precancers and early cancers and (2) to facilitate biology-backed precision prevention approaches.
The TBEL program is a partnership between the Division of Cancer Prevention and the Division of Cancer Biology . All Heading 2s will automatically be pulled in to this list. Do not edit the content on this template.
The progression of an early lesion to malignancy is a complex process that can occur over a period of many years.
Systematic investigations that integrate basic biology and translational efforts to develop mechanistically informed signatures of early lesions and their trajectories over time will allow the establishment of direct relationships between different subtypes of lesions and stromal cells, extracellular matrix and biochemical events in a clinically meaningful manner.
The TBEL program is designed to foster multi-disciplinary collaborations within each Research Center and across the TBEL network to promote a deeper understanding of early lesions, their microenvironment, and reciprocal interactions that drive early lesion fate and clinical outcomes. The TBEL network will include up to five U54 Research Centers.
The U54 Research Centers will integrate basic and translational cancer research studies to iteratively examine the direct causal relationships and interactions of early lesions, their microenvironment, and host-systemic factors as “co-organizers” of tumor initiation (or suppression) and malignant progression in conjunction with the clinical characteristics of the lesions.
Coordinating and Data Management Center (CDMC) The TBEL network will include one U24 Coordinating and Data Management Center (CDMC). The U24 CDMC will (1) coordinate program-wide meetings and conferences, and cross-network collaborative activities; (2) provide statistical and computational analysis support; and (3) serve as a program data hub for data capture, curation and management, and protocol development.
According to the current listing, eligibility includes: Nonprofit organizations, including universities and research institutions. Confirm the full requirements in the official notice before applying.
Coordinating and Data Management Center for Translational and Basic Science Research in Early Lesions is funded by National Cancer Institute (NCI). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
On May 21, 2026, the National Cancer Institute posted RFA-CA-27-006, RFA-CA-27-007, and RFA-CA-27-008 — the three competitive renewals for the NCI Community Oncology Research Program. Combined FY 2027 commitments reach $147.5 million across roughly 57 awards: $74.5 million for up to 7 Research Bases, $73 million for up to 50 Community and Academic Community Sites. Pre-application webinars run June 16-18 this week. Applications are due August 18, 2026 with six-year project periods. For community hospitals, oncology consortia, and NCI-designated cancer centers, this is the single largest cancer clinical-trials infrastructure decision NCI makes until 2033.
Read articleThe Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articlePAR-27-062 creates a three-year, $80,000-salary postdoctoral career award across NCI, NIAID, NIBIB, NIDCR and NINDS — and it carries a hard eligibility window that closes two years after you start your postdoc. Full analysis of the Academic Career Excellence Award, what it replaces, and why the timing rule is the whole competition.
Read article